Professor of Pulmonology. MD, PhD Director of the research unit GETBO, UMR 1304, Brest University Hospital, France. Coordinator of the INNOVTE network.
France
Joined September 2019
- Tweets1.2K
- Following743
- Followers549
- Likes9.8K
Pinned Tweet
Systematic search for PE in COPD ? Read this. Thx to all my collègues.
Pulmonary Embolism Prevalence Among Patients With COPD With Acutely Worsening Respiratory Symptoms ja.ma/2XgJNKI via @JAMA_current part of @JAMANetwork
Francis Couturaud retweeted
Do NOT combine Aspirin and OAC for long-term use - not even in patients at high ASCVD risk!
#AQUATIC confirms for 🇪🇺 patients what has been shown before in East Asian patients.
@escardio #ESCCongress2025
nejm.org/doi/full/10.1056/NE…
Francis Couturaud retweeted
Presented at #ESCCongress:
In patients with chronic coronary syndrome taking oral anticoagulants, adding aspirin led to higher risks of cardiovascular events, major bleeding, and death from any cause than anticoagulation alone. Full AQUATIC trial: nej.md/45AU4Wp
@escardio
ALT Kaplan–Meier curves for a composite of cardiovascular death, myocardial infarction (MI), stroke, systemic embolism, coronary revascularization, or acute limb ischemia (the primary efficacy outcome)
Francis Couturaud retweeted
🫁 Derivation and Validation of a COPD-specific Pulmonary Embolism Diagnostic Strategy ⬇️
📌 Mai et al. derived a #COPD-specific algorithm
📌 Diagnostic failure rate: 0.9%; 53.4% patients would need imaging to rule out #PE
👉 thieme-connect.de/products/e…
#VTE #Thrombosis
Francis Couturaud retweeted
Implementation matters!
A guideline-driven VTE prevention program (Vermont Model) led to ~60% of high-risk cancer patients receiving prophylactic anticoagulation—resulting in a 60% reduction in VTE and 56% reduction in death. #ISTH2025 #VTEprevention 🩸📉
Francis Couturaud retweeted
Do you dose reduce DOAC for extended prevention of VTE?
💙 Post hoc analysis of RENOVE trial of secondary prevention of VTE.
♥️ suggests low dose DOAC may be inferior to full dose among people with BMI >30.
💙 more data is needed
#ISTH2025
Francis Couturaud retweeted
🩸 New insights from the RENOVE trial (extended duration anticoagulation) at #ISTH2025:
📉 Reduced-dose DOAC is non-inferior in patients with BMI <30, with less bleeding risk.
⚠️ But in patients with BMI ≥30, reduced-dose may be inferior for bleeding and recurrent VTE.
➡️ Dose matters!
Fantastic scientific meeting on 6th June 2026 in Brest by our research group @U1304GETBO, with brillant interventions, international leaders in VTE from @INNOVTE1, in Brest. 70 participants. @capucinsbrest, @FCRIN_network, CHU Brest, @UBO_UnivBrest , @Inserm, CIC1412 inserm.
From Steve Noumegni, one of my brightest PhD student. More about predicting both venous and arterial events after VTE. « Prediction of Recurrent Venous Thromboembolism and Arterial Cardiovascular Events after Discontinuation of Anticoag… pubmed.ncbi.nlm.nih.gov/4020…
Francis Couturaud retweeted
Prof. @isabellemahe1 presents API-CAT at #ACC2025, published in @NEJM Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in patients with cancer.
nejm.org/doi/full/10.1056/NE…
Francis Couturaud retweeted
Postpartum hemorrhage is a significant risk for many women yet the etiology is not well understood. New study from @demoreuil and team shows that women with PPH have a different fibrin network than those who did not.
rpthjournal.org/article/S247…
@b_petesch @b_petesch @FCouturaud @Cihan_Ay_MD
RT @MarcCarrier1: The RENOVE trial found that while low-dose DOACs did not meet non-inferiority for preventing recurrent VTE, it showed a b…
Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial - The Lancet thelancet.com/journals/lance…
@INNOVTE1
Francis Couturaud retweeted
René Laënnec, médecin breton, né le 17 février (une belle date) 1781 à Quimper et mort de la tuberculose le 13 août 1826 (à 45 ans) à Douarnenez. Parmi ses nombreuses contributions à la médecine, Laënnec a décrit en quelques mois toute la sémiologie pulmonaire 🫁grâce à son invention géniale, le stéthoscope 🩺 #HistMed
The inventor of the stethoscope, René Laennec, examines a patient in front of his students. Painting by Théobald Chartran c.1816. #histmed #historyofmedicine #stethoscope #pastmedicalhistory
Francis Couturaud retweeted
RENOVE trial: Full dose vs low dose extended anticoagulation in pts requiring long term AC.
Conclusions:
-similar low rate of recurrence (~2%) in both groups
-lower rate of bleeding w low dose
-a chance to compare DOAC efficacy (same!)
-caution w obesity
#ASH24 @FCouturaud
Francis Couturaud retweeted
@ASH_hematology Late Breaking Abstract:
Should patients receive extended duration anticoagulation with reduced or full dose DOAC for the secondary prevention of recurrent VTE - The RENOVE RCT presented by @FCouturaud
Reduced dose DOAC was not non inferior to full dose ((5-year cumulative incidence 2.2% vs 1.8%, P=0.23 for noninferiority) but lower risk of clinically relevant bleeding (9.9 vs 15.2%)! 🩸
Risk benefit seems to favor reduced dosing for most patients #ASH24
Francis Couturaud retweeted
Patients with MPN and splanchnic vein thrombosis who are not receiving anticoagulant therapy seem to have a higher risk of recurrent VTE, bleeding complications and mortality compared to those receiving anticoagulation at 12 months.
#ASH24
Francis Couturaud retweeted
New Genomic Discoveries Pave the Way for Research into Predictive #VT recurrence Factors and Innovative Preventive Strategies
@GaelleMunsch @INNOVTE1 @FCouturaud @morange_pierre @ADJomics @Florian_Th @FritsRosendaal among many others